IOVA in the 13F filings
Iovance Biotherapeutics Inc · CUSIP 462260100
- Quarter end
- 30 Jun 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 3 Aug 2026
- Managers listing it
- 27
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q1 2026 and Q2 2026; 1 listed it in both
- Shares listed
- 52,295,156
- combined, among listed positions
- Reported value
- $217m
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 15 buyers (opened or added shares) and 13 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -1,020,348.
Managers listing IOVA in Q2 2026
27 of 27 holders
Largest increases and reductions, by shares
Increases
- Two Sigma Investments LPexisting position · 19,010,697 shares now+5,323,264
- AQR Capital Management LLCexisting position · 3,869,584 shares now+3,245,416
- Fidelity (FMR LLC)existing position · 1,355,378 shares now+1,306,077
- ExodusPoint Capital Management LPnew position · 270,655 shares now+270,655
- Jane Street Group LLCexisting position · 4,393,853 shares now+219,967
Reductions
- D. E. Shaw & Co.existing position · 2,143,134 shares now-5,873,219
- Marshall Wace LLPexisting position · 39,491 shares now-2,316,121
- Millennium Management LLCexisting position · 8,525,919 shares now-888,373
- T. Rowe Price Associates Incexisting position · 2,415,456 shares now-751,405
- Squarepoint Ops LLCexisting position · 325,582 shares now-706,586
New positions and exits
New (5)
Exited (2)
- Farallon Capital Management LLCwas $91k
- Acadian Asset Management LLCwas $29k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2017 | 1 | $6.6m | n.a. | n.a. |
| Q4 2017 | 1 | $15m | n.a. | n.a. |
| Q1 2018 | 4 | $72m | n.a. | n.a. |
| Q2 2018 | 3 | $59m | n.a. | n.a. |
| Q3 2018 | 3 | $59m | n.a. | n.a. |
| Q4 2018 | 6 | $73m | n.a. | n.a. |
| Q1 2019 | 5 | $70m | n.a. | n.a. |
| Q2 2019 | 5 | $198m | n.a. | n.a. |
| Q3 2019 | 6 | $166m | n.a. | n.a. |
| Q4 2019 | 7 | $333m | n.a. | n.a. |
| Q1 2020 | 9 | $610m | n.a. | n.a. |
| Q2 2020 | 8 | $624m | n.a. | n.a. |
| Q3 2020 | 9 | $822m | n.a. | n.a. |
| Q4 2020 | 9 | $1.8bn | n.a. | n.a. |
| Q1 2021 | 8 | $1.2bn | n.a. | n.a. |
| Q2 2021 | 6 | $917m | n.a. | n.a. |
| Q3 2021 | 7 | $753m | n.a. | n.a. |
| Q4 2021 | 8 | $517m | n.a. | n.a. |
| Q1 2022 | 8 | $423m | n.a. | n.a. |
| Q2 2022 | 7 | $121m | n.a. | n.a. |
| Q3 2022 | 8 | $100m | n.a. | n.a. |
| Q4 2022 | 6 | $43m | n.a. | n.a. |
| Q1 2023 | 6 | $102m | n.a. | n.a. |
| Q2 2023 | 4 | $102m | n.a. | n.a. |
| Q3 2023 | 4 | $35m | n.a. | n.a. |
| Q4 2023 | 7 | $105m | 3 | 4 |
| Q1 2024 | 5 | $154m | 2 | 3 |
| Q2 2024 | 4 | $98m | 1 | 2 |
| Q3 2024 | 4 | $93m | 1 | 2 |
| Q4 2024 | 3 | $52m | 1 | 1 |
| Q1 2025 | 3 | $19m | 1 | 1 |
| Q2 2025 | 1 | $45k | 0 | 1 |
| Q3 2025 | 1 | $56k | 0 | 0 |
| Q4 2025 | 1 | $71k | 15 | 5 |
| Q1 2026 | 2 | $1.3m | 20 | 6 |
| Q2 2026 | 1 | $79m | 15 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
IOVA and GILD →IOVA and AMGN →IOVA and ARGX →Choose a stock to compare with IOVA →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own IOVA, latest filings →Back to the 13F Explorer →